Given the established links between insulin resistance and the development of NAFLD (3), it is possible that IGFBP-2 contributes indirectly to a low LF phenotype by enhancing insulin sensitivity despite the presence of visceral obesity. This evidence concerns the gene IGFBP2 and metabolic dysfunction-associated steatotic liver disease.